Increlex

PreclinicalSmall molecule

Increlex is one of 104 small molecule programs targeting Severe Combined Immunodeficiency. It is currently in Preclinical.

Indications

Total Trials

Active Trials

103

Competitors

Pipeline

Status by Indication[3][1]

Indication

Severe Combined ImmunodeficiencyActive, not recruiting

Liver DiseaseActive, not recruiting

Short StatureActive, not recruiting

GrowthActive, not recruiting

Severe Combined ImmunodeficiencyPhase 1/Phase 2

Active, not recruiting

Liver DiseasePreclinical

Active, not recruiting

Short StaturePhase 1/Phase 2

Active, not recruiting

GrowthPreclinical

Active, not recruiting

Competition

Competitive Landscape

364 competitors in Growth

#DrugCompanyPhaseTrials

Lovenox

Sanofi

Preclinical

2 2

Zolymbus

AbbVie

Preclinical

1 3

Aricept

Eisai

Preclinical

1 4

Zyloprim

Alnylam Pharmaceuticals

Preclinical

1 5

Lenvima

Eisai

Preclinical

1 6

Herceptin

OOrganon and Co

Preclinical

4 7

Somavaratan

EGRIFTA WR

2 9

Trental

VValidus Pharmaceuticals

Preclinical

1 10

Prilosec

DDexcel Pharma Technologies Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Recruiting

Growth

NCT00903110

Clinical

Trials by Indication[1]

Short stature1 trial

IGF-1 Treatment for Individuals With Short Stature Due to PAPP-A2 Deficiency

Completed·—·Phase 1/2·NCT02636270·7 enrolled

Growth1 trial

Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).

Recruiting·EEsteve Pharmaceuticals, S.A.··NCT00903110·500 enrolled

Liver Disease1 trial

Increlex Treatment of Children With Chronic Liver Disease and Short Stature

Withdrawn·UUniversity of California, Los Angeles·N/A·NCT01314508

Concentration1 trial

IGF-I Induced Muscle Glucose Uptake and Interstitial IGF-I Concentrations

Completed·PPeter Bang·N/A·NCT01588093·8 enrolled

Severe Combined Immunodeficiency1 trial

Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency: Phase 2 Study of Insulin-Like Growth Factor-1

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT00490100·6 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Increlex. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Increlex compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Increlex. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Esteve Pharmaceuticals, S.A. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: EEsteve Pharmaceuticals, S.A.

Increlex

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Short stature1 trial

Growth1 trial

Liver Disease1 trial

Concentration1 trial

Severe Combined Immunodeficiency1 trial

References

Drug Info

Quick Facts

Related News